David Voduc

11.8k total citations · 4 hit papers
20 papers, 8.0k citations indexed

About

David Voduc is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, David Voduc has authored 20 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Cancer Research and 4 papers in Molecular Biology. Recurrent topics in David Voduc's work include Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Lesions and Carcinomas (4 papers). David Voduc is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Lesions and Carcinomas (4 papers). David Voduc collaborates with scholars based in Canada, United States and Spain. David Voduc's co-authors include Torsten O. Nielsen, Maggie C.U. Cheang, Samuel Leung, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis, Joel S. Parker, Sherri R. Davies, Stephen Chia and Karen A. Gelmon and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Surgery.

In The Last Decade

David Voduc

20 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 3.1k citations Joel S. Parker, Michael E. Mullins et al. Journal of Clinical Oncology profile →
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. JNCI Journal of the National Cancer Institute profile →
Metastatic Behavior of Breast Cancer Subtypes

2010 1.6k citations Hagen F. Kennecke, Rinat Yerushalmi et al. Journal of Clinical Oncology profile →
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

2008 945 citations Maggie C.U. Cheang, David Voduc et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by David Voduc

Since Specialization

Citations

This map shows the geographic impact of David Voduc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Voduc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Voduc more than expected).

Fields of papers citing papers by David Voduc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Voduc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Voduc. The network helps show where David Voduc may publish in the future.

Co-authorship network of co-authors of David Voduc

This figure shows the co-authorship network connecting the top 25 collaborators of David Voduc. A scholar is included among the top collaborators of David Voduc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Voduc. David Voduc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes 2023 ·Journal of Clinical Oncology ·Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang, Samuel Leung, David Voduc, Tammi L. Vickery, Sherri R. Davies, (unknown), Xiaping He, Zhiyuan Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J. S. Marron, Andrew B. Nobel, Elaine R. Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. Bernard	23
2	Neoadjuvant Systemic Therapy in Breast Cancer: Use and Trends in Radiotherapy Practice 2017 ·Current Oncology ·(unknown), (unknown), Caroline Speers, Scott Tyldesley, David Voduc, Christine Simmons, Robert Olson	3
3	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials 2017 ·Acta Oncologica ·(unknown), Trine Tramm, Torsten O. Nielsen, Jan Alsner, Silje Nord, Simen Myhre, Thérese Sørlie, Samuel Leung, Cheng Fan, Charles M. Perou, Karen A. Gelmon, Jens Overgaard, David Voduc, Aleix Prat, Maggie C.U. Cheang	21
4	Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy 2015 ·Journal of Clinical Oncology ·Fei‐Fei Liu, Wei Shi, Susan J. Done, Naomi Miller, Melania Pintilie, David Voduc, Torsten O. Nielsen, Sharon Nofech‐Mozes, Martin C. Chang, Timothy J. Whelan, Lorna Weir, Ivo A. Olivotto, David R. McCready, Anthony Fyles	96
5	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. 2012 ·Journal of Clinical Oncology ·Maggie C.U. Cheang, Miguel Martín, Torsten O. Nielsen, Aleix Prat, Álvaro Rodríguez-Lescure, Amparo Ruı́z, Stephen Chia, Lois E. Shepherd, David Voduc, Philip S. Bernard, Matthew J. Ellis, Charles M. Perou, Angelo Di Leo, Lisa A. Carey, (unknown)	10
6	HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival 2010 ·Annals of Surgery ·Connie G. Chiu, Hamid Masoudi, Samuel Leung, David Voduc, C. Blake Gilks, David G. Huntsman, Sam M. Wiseman	45
7	Metastatic Behavior of Breast Cancer Subtypes breakdown → 2010 ·Journal of Clinical Oncology ·Hagen F. Kennecke, Rinat Yerushalmi, Ryan Woods, Maggie C.U. Cheang, David Voduc, Caroline Speers, Torsten O. Nielsen, Karen A. Gelmon	1633
8	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes breakdown → 2009 ·Journal of Clinical Oncology ·Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang, Samuel Leung, David Voduc, Tammi L. Vickery, Sherri R. Davies, (unknown), Xiaping He, Zhiyuan Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J. S. Marron, Andrew B. Nobel, Elaine R. Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. Bernard	3093
9	Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer breakdown → 2009 ·JNCI Journal of the National Cancer Institute ·Maggie C.U. Cheang, Stephen Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri R. Davies, Philip S. Bernard, Joel S. Parker, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen	1641
10	α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis 2009 ·Journal of Clinical Oncology ·Hagen F. Kennecke, David Voduc, Suet Yi Leung, Vincent L. Cryns, Charles M. Perou, Torsten O. Nielsen, Maggie C.U. Cheang	1
11	Response: Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer 2009 ·JNCI Journal of the National Cancer Institute ·Torsten O. Nielsen, Maggie C.U. Cheang, Stephen Chia, David Voduc, Dongxia Gao, Samuel Leung, Philip S. Bernard, Charles M. Perou, Matthew J. Ellis	31
12	Tissue Microarrays in Clinical Oncology 2008 ·Seminars in Radiation Oncology ·David Voduc, (unknown), Torsten O. Nielsen	95
13	The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype 2008 ·Human Pathology ·David Voduc, Torsten O. Nielsen, Maggie C.U. Cheang, William D. Foulkes	36
14	Basal and Triple-Negative Breast Cancers: Impact on Clinical Decision-Making and Novel Therapeutic Options 2008 ·Clinical Breast Cancer ·David Voduc, Torsten O. Nielsen	12
15	Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype breakdown → 2008 ·Clinical Cancer Research ·Maggie C.U. Cheang, David Voduc, Chris Bajdik, Samuel Leung, Steven McKinney, Stephen Chia, Charles M. Perou, Torsten O. Nielsen	945
16	GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value 2008 ·Cancer Epidemiology Biomarkers & Prevention ·David Voduc, Maggie C.U. Cheang, Torsten O. Nielsen	119
17	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases 2007 ·Breast Cancer Research and Treatment ·Ashish Rajput, Dmitry Turbin, Maggie C.U. Cheang, David Voduc, Sam Leung, Karen A. Gelmon, C. Blake Gilks, David G. Huntsman	158
18	Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002 2006 ·Urology ·Scott Tyldesley, David Voduc, Michael McKenzie, Graeme Duncan, Mitchell Liu, (unknown)	14
19	The Effect of Smoking on Tumour Oxygenation and Treatment Outcome in Cervical Cancer 2002 ·Clinical Oncology ·Anthony Fyles, David Voduc, A.M. Nisar Syed, Michael Milosevic, Melania Pintilie, Rićhard P. Hill	11
20	The effect of smoking on tumor oxygenation and treatment outcome in cervical cancer 2001 ·International Journal of Radiation OncologyBiologyPhysics ·David Voduc, A.M. Nisar Syed, Michael Milosevic, Melania Pintilie, Anthony Fyles	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact